| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 941.45% | Wedbush | → $5 | Reiterates | Outperform → Outperform |
| 09/29/2023 | 212.43% | HC Wainwright & Co. | → $1.5 | Initiates Coverage On | → Buy |
| 06/05/2023 | 1149.74% | Wedbush | $4 → $6 | Maintains | Outperform |
| 05/30/2023 | 1566.32% | SVB Securities | $5 → $8 | Upgrades | Market Perform → Outperform |
| 03/10/2023 | 733.16% | Wedbush | → $4 | Reiterates | → Outperform |
| 01/09/2023 | 108.29% | SVB Leerink | $2 → $1 | Maintains | Market Perform |
| 11/10/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/07/2022 | 316.58% | SVB Leerink | $11 → $2 | Downgrades | Outperform → Market Perform |
| 09/19/2022 | 1462.17% | HC Wainwright & Co. | → $7.5 | Assumes | → Buy |
| 08/08/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/04/2022 | 4274.09% | Wedbush | $27 → $21 | Maintains | Outperform |
| 12/23/2021 | 2399.48% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/20/2021 | 5523.83% | Wedbush | → $27 | Initiates Coverage On | → Outperform |
| 07/20/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/20/2021 | 4065.8% | SVB Leerink | → $20 | Initiates Coverage On | → Outperform |
What is the target price for Elevation Oncology (ELEV)?
The latest price target for Elevation Oncology (NASDAQ: ELEV) was reported by Wedbush on November 6, 2023. The analyst firm set a price target for $5.00 expecting ELEV to rise to within 12 months (a possible 941.45% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Elevation Oncology (ELEV)?
The latest analyst rating for Elevation Oncology (NASDAQ: ELEV) was provided by Wedbush, and Elevation Oncology reiterated their outperform rating.
When is the next analyst rating going to be posted or updated for Elevation Oncology (ELEV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevation Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevation Oncology was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating Elevation Oncology (ELEV) correct?
While ratings are subjective and will change, the latest Elevation Oncology (ELEV) rating was a reiterated with a price target of $0.00 to $5.00. The current price Elevation Oncology (ELEV) is trading at is $0.48, which is within the analyst's predicted range.